Trial Profile
An Open-Label Study to Assess the Efficacy And Safety of Poly(ADP-ribose) Polymerase Inhibitor FluzoparibSHR3162in Patients With Relapsed High-grade Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer and BRCA1/2 Mutation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Oct 2021
Price :
$35
*
At a glance
- Drugs Fuzuloparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 15 Oct 2021 Status changed from active, no longer recruiting to completed.
- 08 Feb 2021 Primary endpoint (ORR by RECIST v1.1) has been met, as per results published in the Clinical Cancer Research
- 08 Feb 2021 Results published in the Clinical Cancer Research